[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Invicro\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":79},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100619717","early-phase-1-open-label-study-to-evaluate-brain--synuclein-deposition-using-pet-and-18fmk-0947-in-parkinsons-disease-100619717",false,"NCT07348250","Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease","An Open-label Study to Evaluate Brain α-Synuclein Deposition Using Positron Emission Tomography (PET) and [18F]MK-0947 in Patients With Parkinson's Disease","Inclusion Criteria:\n\n* Signed informed consent prior to any study procedures\n* Women of childbearing potential: abstinent or use 2 contraception methods (one barrier) during study and 90 days post last injection\n* Men: use 2 contraception methods and refrain from sperm donation during study and 90 days post last injection\n* PD \\& HE participants: Age 40-80 years; HP participants: Age 18-50 years\n* Adequate circulation and normal clotting for arterial cannulation (if applicable)\n* HE participants: no neurological disorder, no first-degree relative with idiopathic PD\n* HP participants: healthy with no clinically relevant findings\n\nExclusion Criteria:\n\n* Unwilling or unable to provide informed consent\n* Clinically significant hepatic, renal, cardiovascular, pulmonary, or systemic illness\n* Pregnant or breastfeeding\n* Contraindication to PET or MRI procedures (e.g., implants, claustrophobia)\n* History of severe allergic reactions to PET tracers or related compounds\n* Current or prior participation in investigational drug study within 30 days\n* Any condition that may interfere with study conduct or participant safety",true,"ALL","18 Years","80 Years",{"count":21,"type":22},22,"ESTIMATED","INTERVENTIONAL",[25],"EARLY_PHASE1","This clinical study is being conducted to learn more about a new imaging drug called \\[18F\\]MK-0947, which is designed to help doctors see changes in the brain related to Parkinson's disease (PD). PD is a condition that affects movement, balance, and thinking. The drug works with a type of scan called PET (Positron Emission Tomography) to show areas of the brain where a protein called α-synuclein builds up. This buildup is linked to PD and other brain disorders.\n\nThe main goal of this study is to find out if \\[18F\\]MK-0947 is safe for people and if it works well to show α-synuclein in the brain. The study will also look at how the drug moves through the body and how much radiation it gives off. Researchers hope this information will help develop better tools for diagnosing PD and tracking how it changes over time.\n\nWho can join? Adults who have PD or who are healthy may be able to take part. Participants will have screening tests to make sure they qualify.\n\nWhat does participation involve? People in the study will have PET scans, blood tests, and other safety checks. Some participants will also have an MRI scan. The study is divided into two parts: Part 1 looks at how the drug works in the brain of PD patients and healthy elderly participants, and Part 2 measures radiation levels in healthy participants.\n\nWhy is this important? There is currently no cure for PD, and better imaging tools could help researchers develop new treatments. By joining this study, participants will help advance research that may improve care for people with PD and similar conditions in the future.",[28,29,30],"Parkinson's Disease (PD)","Parkinson's Disease","Parkinson's Disease (Disorder)",[32,33,34,35],"alpha-synuclein","α-synuclein","Neurodegeneration","MK-0947","RECRUITING","2026-06-24",{"date":39,"type":40},"2026-06-26","ACTUAL",{"date":42,"type":40},"2025-12-08",{"date":44,"type":22},"2026-12",{"name":46,"class":47},"Invicro","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},"100619719","early-phase-1-first-in-human-study-for-the-safety-and-evaluation-of-two-4r-tau-ligands-as-potential-pet-radioligands-for-imaging-tau-protein-in-the-brain-100619719","NCT07348276","First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain","First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands ([18F]ABBV964i and [ 18F]ABBV-965i) as Potential PET Radioligands for Imaging Tau Protein in the Brain of Patients With Probable PSP and Healthy Volunteers","Inclusion Criteria:\n\n* Males or females: PSP 40-80 years; HV 18-80 years\n* Body weight: 43-120 kg (95-265 lb)\n* Women of childbearing potential: abstinent or use 2 contraception methods (one barrier) during study and 30 days post last injection\n* Men: use 2 contraception methods and refrain from sperm donation during study and 90 days post last injection\n* Adequate circulation and normal clotting for arterial cannulation\n* Sufficient mobility and ability to lie still for imaging\n* Healthy Volunteers: informed consent, no clinically relevant findings, no cognitive impairment\n* PSP Participants: informed consent or assent with LAR consent, clinical diagnosis per NINDS-SPSP criteria, MRI consistent with PSP, able to ambulate, tolerate MRI, comply with study procedures, caregiver available if needed\n\nExclusion Criteria:\n\n* History of drug or alcohol abuse in past 12 months\n* Clinically significant lab abnormalities or unstable illness\n* Investigational drug\u002Fdevice use within 30 days\n* Pregnant, lactating, or breastfeeding\n* Significant comorbid conditions (GI, CV, hepatic, renal, etc.)\n* Abnormal clotting parameters (if arterial sampling)\n* MRI contraindications (implants, claustrophobia) for PSP participants\n* Use of OTC meds or supplements within 2 weeks (healthy volunteers)\n* Use of anti-hemostasis meds within 2 weeks of arterial line placement for PSP participants\n* Unable to lie still for 90 minutes\n* Major surgery or significant blood loss within 4 weeks\n* Positive for Hepatitis B, Hepatitis C, or HIV\n* Deemed unsuitable by Investigator",{"count":56,"type":22},24,[25],"This clinical study is being conducted to learn more about two new imaging drugs, called \\[18F\\]ABBV-964i and \\[18F\\]ABBV-965i, which are designed to help doctors see changes in the brain related to a condition called Progressive Supranuclear Palsy (PSP). PSP is a rare disease that affects movement, balance, and thinking. These drugs are used with a type of scan called PET (Positron Emission Tomography) to show areas of the brain where a protein called tau builds up. Tau buildup is linked to PSP and other brain diseases.\n\nThe main goal of this study is to find out if these imaging drugs are safe for people and if they work well to show tau in the brain. The study will also look at how the drugs move through the body and how much radiation they give off. Researchers hope this information will help develop better tools for diagnosing PSP and tracking how it changes over time.\n\nWho can join? Adults who are healthy or who have PSP may be able to take part. Participants will have screening tests to make sure they qualify.\n\nWhat does participation involve? People in the study will have PET scans, blood tests, and other safety checks. Some participants will also have an MRI scan. The study is divided into three parts: Part A checks radiation levels in healthy volunteers, Part B looks at how the drugs work in the brain of PSP patients and healthy volunteers, and Part C (optional) repeats scans to see if results are consistent.\n\nWhy is this important? There is currently no cure for PSP, and better imaging tools could help researchers develop new treatments. By joining this study, participants will help advance research that may improve care for people with PSP and similar conditions in the future.",[60,61],"Progressive Supranuclear Palsy (PSP)","Healthy Participants",[63,64,65,66,67,68,69],"Tauopathy","Tau","PET Imaging","ABBV-965i","ABBV-964i","PSP","Progressive Supranuclear Palsy","2026-01-09",{"date":72,"type":40},"2026-01-16",{"date":74,"type":40},"2025-11-17",{"date":76,"type":22},"2027-03",{"name":46,"class":47},1,""]